Acquisition momentum KOVA International has been acquired by LGC Group in 2023, signaling ongoing corporate support and potential integration opportunities with larger diagnostics ecosystems for cross-sell of quality control and urinalysis products.

Quality control focus Specializes in in vitro urinalysis and toxicology quality control products for clinical laboratories, presenting a ready-made entry point for partnerships with clinical labs, reference laboratories, and hospital systems seeking QC solutions.

Tech-enabled ops Utilizes cloud and modern tech tools (AWS, HubSpot analytics, WordPress, Office 365) which can support scalable sales outreach, CRM automation, and data-driven account targeting to accelerate adoption in mid-market labs.

Growth through synergy Aligned under SeraCare Clinical Diagnostics within the LGC Diagnostics & Genomics brand, offering potential bundled solutions or co-marketing across the extended diagnostics family to win larger lab contracts.

Market signals Current revenue range and small to mid-size employee base indicate a niche, potentially underserved segment in clinical labs; consider targeting mid-sized hospital networks and regional labs with urgent QC needs and favorable procurement cycles.